Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDOX-guided TACE in Hepatocellular Carcinoma
NCT05766605Phase 3Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of oxaliplatin, doxorubicin, lobaplatin, cisplatin, fluorouracil and 1 more in hepatocellular carcinoma (HCC) (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Disease-Free Survival at 1 year. Started Jan 2023; status: recruiting.
02
Drugs
oxaliplatindoxorubicinlobaplatincisplatinfluorouracil
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05766605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766605.